Exagen (XGN) Current Deferred Revenue (2024 - 2026)

Exagen (XGN) has reported Current Deferred Revenue for 3 consecutive years, with $700000.0 the latest figure, recorded in Q1 2026.

• Current Deferred Revenue for Q1 2026 came in at $700000.0, down 22.22% year-over-year; the trailing twelve-month figure through Mar 2026 was $700000.0 (down 22.22% YoY), and the FY2025 annual result was $700000.0, down 4.5% from the prior year.
• Current Deferred Revenue was $700000.0 for Q1 2026 at Exagen, roughly flat from $700000.0 in the prior quarter.
• Over five years, Current Deferred Revenue peaked at $1.0 million in Q2 2025 and troughed at $600000.0 in Q3 2025.
• Average Current Deferred Revenue over 3 years is $772166.7, with a median of $716500.0 recorded in 2024.
• Year-over-year, Current Deferred Revenue declined 4.5% in 2025 and retreated 22.22% in 2026.
• Over 3 years, Current Deferred Revenue stood at $733000.0 in 2024, then decreased by 4.5% to $700000.0 in 2025, then changed by 0.0% to $700000.0 in 2026.
• Per Business Quant data, the three most recent Current Deferred Revenue figures were $700000.0 in Q1 2026, $700000.0 in Q4 2025, and $600000.0 in Q3 2025.